Here is yet another article for the readers if they want to know more about CCR5 since Desai continues to ignore data on the topic. www.medrxiv.org/.../2020.05.02.20084673v1.full.pdf

I don't think we should expect or count on a vaccine. The odds are slim one will work effectively enough to grant social immunity. Even if it did, getting people to pay for it and take it will take months, if not years given it is being politicized and we don't have a national health care system. Global growth for the US will largely be dependent of the election amazingly, with Trump being a barrier to globalism. Tech will still dominate along with biotech. However, the extremes will be toned down with Facebook, Tesla, etc. not growing as rapidly as financial strength over growth starts dominating. I expect a housing/property collapse before a major market meltdown.

There is not a shortage of goods and services and won;t be in the US for a while. The issue is more a consumption one which was predicted as the baby boomer cycle ends. Unfortunately Covid is speeding up this transition. Likewise, the concept that housing demand will rise will be put to the test in the coming years in the US as the baby boomers pass away lowering demand, with the government stopping stimulus it will drag the economy down until stimulus is resumed and it starts to have an effect, and as Covid persists demand will wane. This is why I believe we will hit a housing crisis before a major stock meltdown, although there will be downturns here and there. The stock market it the best hope you have of generating decent returns and potentially growing in this environment and is why it is being blown up along with other assets bubbles.

Your article is making the case that neutrophils determine the severity of COVID-19. Severity is clearly correlated to the comorbidities of COVID-19. To prove that point there has to be some linkage between the comorbidities and neutrophils. When they do the UMAP presentation they use a healthy person. If the goal of the article is talking about predicting severity is should have compared to a diabetes patient or a hypertension patient. It did not. The comparison to covid state in the article is just an observation of what the end result of the disease is. If we follow your logic then blocking neutrophils will cure the disease. That is not the case. It will would help but its not a panacea. Neutrophils are just one of many immune cells. Blocking CCR5 results in blocking the macrophages that are primarily responsible for the signaling cascade. It is a multi pronged approach. That’s what leronlimab does. Regarding peer review, I will take wired and others journalistic integrity over an article that in no way says CCR5 is no good and which you wrongly assume blocking neutrophils will cure the disease which it won't. You are free to look on google regarding CCR5 and Covid. There are a lot and papers that are downloadable. However, I don't link them because people don't wantto go to a ling that downloads a scholarly paper to read. If you want you can go to research square and look up: Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19 to read a professional scolarly rticle if you think the tons of press articles on this are garbage along with the tons of doctors cited in them. https://insight.jci.org/articles/view/139834 www.ncbi.nlm.nih.gov/pmc/articles/PMC7277012/ www.ncbi.nlm.nih.gov/pmc/articles/PMC7406242/ air.unimi.it/.../...EAE6347C985.suir-unimi-prod-02 I will not due your homework anymore but posted what I did as a service to all those who want to know the truth about your incorrect allegation against the scientific nature of Covid. Don't bother the informed with outlandish accusations.

Agreed, I suggest people do a bit of their own research on this. The price is low partially due to the big dissonance between the bulls and the bears. Then follow the science.

You are right that even the successful food stores are coming under pressure as the beaten down chains start to adapt. Costs in general have gone up for everyone as well as the difficulties in selling and providing food to customers. That is, until lots of these restaurants determine to save money on rent and property.

One article doesn't make scientific fact. This is why there is a scientific procedure, not conjecture being studied. Your arguments saying things aren't worth studying because you found something that fits your conclusion is not worth studying because you found something that fits your conclusion is not scientific and undermines what the FDA is doing, authorizing and managing clinical studies to determine scientific fact.

And no, Cytodyn isn't the only one identifying this link to fight Covid. It so happens to be the first drug going through the FDA approval to help those with Covid.

https://pubmed.ncbi.nlm.nih.gov/32511656/

www.wired.com/.../why-does-covid-19-make-some-people-so-sick-ask-their-dna/

www.peakprosperity.com/.../any-populations-with-natural-genetic-resistance-to-covid-19/

magazine.jhsph.edu/.../clues-covid-19-severity-may-lie-our-genes

www.pharmacytimes.com/.../novel-drug-may-reduce-inflammation-in-critical-covid-19-patients

It is hilarious that you think responding to commenters on their own article is disingenuous. So you are saying not responding is showing what? That people can spout idiocracy without being corrected. If so, I'm sure you will say not responding is showing a guilty conscience too. If your logic is that anyone disagreeing with you is wrong it is more likely you are the one spouting falsehoods. I can equally say your mad posting on all boards spouting rumors and innuendo about Cytodyn shows both your bias and your position, not that it makes a difference. My readers aren't stupid.

Yawn.

1. Look at phase II results. It exhibited traits that existing drugs don't address and met the safety profile it was meant to prove. Even so, with a small sample size as a phase II it almost met the primary endpoint which is not expected. Read FDA results. I agree that it may be suitable for HIV.

2-3. Nasdaq approval isn't off the table and the major concern is price volatility which may be moderated especially after an approval as will better funding options just like all pharmaceutical companies. That said, it has plenty of cash to operate currently and will make adjustments as they see fit.

4-5. NASH trials are suppose to determine NASH results as are other study results. The FDA has not cited any of their studies as deficient to prove their points.

6. It is funny you mention studies on this. There have been numerous pre-FDA study results by doctors which have been cited by bears as being indicative of its ability and not proof thus is why one does FDA studies which were used to get FDA studies authorized. Blaming the egg for not being a chicken is a rather dumb argument in my book. Here are some as you claim unpublished articles on the topic. You are welcome to google this subject yourself:

www.cytodyn.com/.../cytodyn-reports-strong-results-from-eind-covid-19-patients

www.targetedonc.com/.../leronlimab-shows-further-promise-for-covid-19-treatment-study-shows

apnews.com/.../5f340ac37ee044e098fd1a843cb46b08

http://www.bioquicknews.com/node/5315

www.biospace.com/article/clinical-catch-up-may-4-8/

7. This is just something that was disclosed recently and may be a sign it can help people who may suffer from Covid related brain hemorrhages. The science has yet to be studied in depth or proven one way or another. Thus its too early to call and is fine to announce.

8. Who are you to say one drug is better than another. This is what regulatory bodies are for. You are injecting opinion not science into the argument.

9. This is just spiteful bear ranting. It makes me wonder why I even bother responding to such comments. Write your own article and be judged on it by your peers.

I'm amazed that people want to sell during this crisis. However, I'm equally amazed people want to buy during Covid and that the rental, commercial property market isn't collapsing.